Palvella Therapeutics (PVLA) Enterprise Value (2013 - 2026)
Palvella Therapeutics (PVLA) reported Enterprise Value of -$261.9 million for Q1 2026, down 246.25% year-over-year from $179.0 million in Q1 2025, and down 351.61% on a QoQ basis from -$58.0 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Enterprise Value data on file, last reported at -$261.9 million in Q1 2026.
- Quarterly Enterprise Value fell 246.25% year-over-year to -$261.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$261.9 million (down 246.25% YoY) and the FY2025 annual result came in at -$58.0 million, up 30.65% from the prior year.
- Enterprise Value eased to -$261.9 million in Q1 2026 per PVLA's latest filing, from -$58.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$6.2 million in Q1 2024 and bottomed at -$261.9 million in Q1 2026.
- The 5-year median for Enterprise Value is -$63.6 million (2025), against an average of -$67.3 million.
- The widest annual swing landed in 2024, when Enterprise Value soared 87.09%; it then sank 1110.4% in 2025.
- Tracing PVLA's Enterprise Value over 5 years: stood at -$59.2 million in 2022, then soared by 72.42% to -$16.3 million in 2023, then slumped by 412.27% to -$83.6 million in 2024, then soared by 30.65% to -$58.0 million in 2025, then sank by 351.61% to -$261.9 million in 2026.
- Per Business Quant, the three latest PVLA Enterprise Value figures stand at -$261.9 million (Q1 2026), -$58.0 million (Q4 2025), and -$63.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | -261.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -261.85 Mn |
| Dec 31, 2025 | -57.98 Mn |
| Sep 30, 2025 | -63.57 Mn |
| Jun 30, 2025 | -70.43 Mn |
| Mar 31, 2025 | -75.63 Mn |
| Dec 31, 2024 | -83.60 Mn |
| Sep 30, 2024 | -14.21 Mn |
| Jun 30, 2024 | -14.54 Mn |
| Mar 31, 2024 | -6.25 Mn |
| Dec 31, 2023 | -16.32 Mn |
| Sep 30, 2023 | -56.72 Mn |
| Jun 30, 2023 | -64.84 Mn |
| Mar 31, 2023 | -48.38 Mn |
| Dec 31, 2022 | -59.17 Mn |
| Sep 30, 2022 | -69.82 Mn |
| Jun 30, 2022 | -80.94 Mn |
| Mar 31, 2022 | -100.27 Mn |
| Dec 31, 2021 | -117.76 Mn |
| Sep 30, 2021 | -34.90 Mn |
| Jun 30, 2021 | -91.80 Mn |
| Mar 31, 2021 | -66.84 Mn |
| Dec 31, 2020 | -70.44 Mn |
| Sep 30, 2020 | -82.64 Mn |
| Jun 30, 2020 | -77.21 Mn |
| Mar 31, 2020 | -86.76 Mn |
| Dec 31, 2019 | -104.15 Mn |
| Sep 30, 2019 | -86.24 Mn |
| Jun 30, 2019 | -99.68 Mn |
| Mar 31, 2019 | -110.78 Mn |
| Dec 31, 2018 | -125.18 Mn |
| Sep 30, 2018 | -137.30 Mn |
| Jun 30, 2018 | -150.98 Mn |
| Mar 31, 2018 | -159.58 Mn |
| Dec 31, 2017 | -72.63 Mn |
| Sep 30, 2017 | -89.92 Mn |
| Jun 30, 2017 | -50.32 Mn |
| Mar 31, 2017 | -55.24 Mn |
| Dec 31, 2016 | -29.36 Mn |
| Sep 30, 2016 | -36.56 Mn |
| Jun 30, 2016 | -40.37 Mn |
| Mar 31, 2016 | -31.19 Mn |
| Dec 31, 2015 | -29.35 Mn |
| Sep 30, 2015 | -32.25 Mn |
| Jun 30, 2015 | -10.03 Mn |
| Mar 31, 2015 | -13.17 Mn |
| Dec 31, 2014 | -18.47 Mn |
| Sep 30, 2014 | -936,183.00 |
| Jun 30, 2014 | -1.49 Mn |
| Mar 31, 2014 | -3.27 Mn |
| Dec 31, 2013 | -3.69 Mn |
| Sep 30, 2013 | -688.00 |
| Jun 30, 2013 | -5,200.00 |